Oxford BioTheraputics Names Abderrahim Fandi as CMO

Abderrahim Fandi, formerly of Celgene, has joined Oxford BioTherapeutics as the company’s CMO. His position will be responsible for developing OBT’s immuno-oncology candidates.

Rahim brings a wealth of drug development expertise to OBT, which will significantly benefit the company as we move our clinical development program forward in the United States for MEN1309, our novel ADC therapy [that’s] currently undergoing clinical testing in Europe,” said OBT CEO Christian Rohlff in a recent statement.[1]

The press release announces that Dr. Fandi has led the development of several oncology compounds and participated in successful regulatory interactions, including many with the FDA. He has also held positions at Novartis, BMS, AstraZeneca, and Sanofi Aventis, and has contributed to over 100 peer-reviewed publications and abstracts. In addition, he has served as first author in lead journals, including the Journal of Clinical Oncology.

To read the full press release from Oxford BioTherapeutics, visit PharmiWeb.com.


[1] https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=267248


Will Chipotle’s Investment In Education Pay Off For Its Employees?
April 20, 2021
Chipotle launched its new debt-free tuition program for its employees. The program will cover those majoring in agriculture, culinary, and hospitality industries. The move shows intention for how the QSR values Read more
Track to the Future: Array Technologies Achieves ISO 9001:2015 Certification
April 20, 2021
Array Technologies recently completed its ISO audits and ISO certification. This exciting step in Array Technologies' growth was the main topic of conversation for this episode of Track to the Future. Travis Read more
E2B: Energy Industry Cybersecurity Threats In The Digital Age
April 20, 2021
  Are energy companies taking cybersecurity seriously? Are they shifting focus to application security? E2B host Daniel Litwin speaks with Dan Cornell, Chief Technology Officer of the Denim Group and Kent Read more